What is the clinical evidence from this study?

Study design: Case-Control. Population: Dilated Cardiomyopathy (n=35). Intervention: Dilated Cardiomyopathy vs. Control subjects. Primary outcome: TACE mRNA expression (TACE/GAPDH ratio) (p=<0.05).

What question did this study set out to answer?

The study aims to investigate the expression of TACE and TNF-alpha in the myocardium and their correlation with the severity of dilated cardiomyopathy.

June 29, 1999Circulation

Tumor Necrosis Factor-α–Converting Enzyme and Tumor Necrosis Factor-α in Human Dilated Cardiomyopathy

Q: What are the key findings of this study?

Patients with dilated cardiomyopathy had significantly greater myocardial TACE mRNA expression than control subjects (TACE/GAPDH ratio 2.52 vs 0.03, P<0.05).

Q: What question did this study set out to answer?

The study aims to investigate the expression of TACE and TNF-alpha in the myocardium and their correlation with the severity of dilated cardiomyopathy.

View Full Paper

Ask AI

Bookmark

Key result

Dilated cardiomyopathy is linked to markedly higher myocardial TACE mRNA expression vs controls.

P<0.05
n=35

Why the study?

Tumor necrosis factor-alpha (TNF-alpha) and its converting enzyme (TACE) have been implicated in dilated cardiomyopathy, but their myocardial expression and relation to clinical severity were unclear.

Key Points

The study aims to investigate the expression of TACE and TNF-alpha in the myocardium and their correlation with the severity of dilated cardiomyopathy.
Endomyocardial tissues obtained from 30 DCM patients and 5 controls
Measured TNF-alpha and TACE mRNA levels using real-time quantitative reverse transcriptase-polymerase chain reaction
Determined protein expression via immunohistochemical analysis
TNF-alpha mRNA detected in DCM patients (TNF-alpha/GAPDH ratio 0.85±0.24); absent in controls.
TACE mRNA significantly higher in DCM patients (TACE/GAPDH ratio 2.52±0.59 vs 0.03±0.02, P<0.05).
Positive correlation (r=0.779, P<0.001) between TNF-alpha and TACE mRNA levels in DCM patients.

Study Design

Type

Case-Control (n=35)

Structured PICO

Population

30 patients with dilated cardiomyopathy and 5 control subjects evaluated for myocardial TACE and TNF-alpha expression.

Comparator

5 control subjects

Outcome

Myocardial TNF-alpha and TACE mRNA and protein expression levelssurrogate

Main Result

Absolute Event Rate: 2.52% vs 0.03%

p-value: p=<0.05

Increased myocardial TACE expression is associated with elevated TNF-alpha expression and correlates with clinical severity (lower LVEF and higher LVESD) in patients with dilated cardiomyopathy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports TACE as a potential TNF-alpha mediator in DCM; hypothesis-generating for targeted inhibition.

Cite This Study

Satoh et al. (1999) conducted a case-control in Dilated Cardiomyopathy (n=35). Dilated Cardiomyopathy vs. Control subjects was evaluated on TACE mRNA expression (TACE/GAPDH ratio) (p=<0.05). Patients with dilated cardiomyopathy had significantly greater myocardial TACE mRNA expression than control subjects (TACE/GAPDH ratio 2.52 vs 0.03, P<0.05).

synapsesocial.com/papers/6a6264886e9a4038e37daeb2 https://doi.org/10.1161/01.cir.99.25.3260

View Full Paper

Ask AI

Bookmark

Tumor Necrosis Factor-α–Converting Enzyme and Tumor Necrosis Factor-α in Human Dilated Cardiomyopathy

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Tumor Necrosis Factor-α–Converting Enzyme and Tumor Necrosis Factor-α in Human Dilated Cardiomyopathy

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider